Cyclin D1 G870A polymorphism and breast cancer risk

A meta-analysis involving 23,998 subjects

June Yang, Hong Liu, Su Lu, Maolong Gao, Qiuyue Du, Shou Ching Tang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cyclin D1 (CCND1) plays an essential role in tumor development and progression through regulating the cell transition from G1 to the proliferative S phase. The CCND1 G870A polymorphism has been associated with an increased susceptibility to squamous cell carcinoma of the head and neck, bladder, prostate, and gastric cardiac cancers. There are a number of studies that explored the relationship between CCND1 G870A polymorphism and breast cancer risk, with inconsistent conclusions. In order to better define the predictive value of CCND1 G870A polymorphism in breast cancer, we searched PubMed and EBSCO for relevant publications. A total of 13 studies were indentified, which included 11,235 cases and 12,763 controls. We calculated the summary odds ratios and the corresponding 95% confidence interval. Our meta-analysis showed that carriers of AA genotype have a significantly higher risk in developing breast cancer compared with that of GG genotype (OR = 1.08, 95% CI = 1.01-1.17, p> = 0.03) in overall population. Furthermore, in subgroup analysis, CCND1 G870A polymorphism was associated with a marginally increased risk of breast cancer for Chinese compared to Caucasian populations with an OR = 1.14, 95% CI = 1.00-1.20, ptrend = 0.06 for AA + GA versus GG, if the controls were hospital-based population with an OR = 1.21, 95% CI = 0.99-1.47, p = 0.06 for AA versus GG and if the distributions of genotypes in control groups were consistent with the Hardy-Weinberg equilibrium (HWE) with an OR = 1.08, 95% CI = 1.00-1.15, p = 0.04 for AA versus GA + GG. Our meta-analysis represents the largest study to date indicating that the G870A polymorphism in CCND1 confers an increased risk for breast cancer. Further studies are warranted to explore the preventive measures to detect and manage the breast cancers attributable to the G870A polymorphism.

Original languageEnglish (US)
Pages (from-to)519-525
Number of pages7
JournalOncology Research
Volume19
Issue number12
DOIs
StatePublished - Jun 7 2012

Fingerprint

Cyclin D1
Meta-Analysis
Breast Neoplasms
Genotype
Population
Heart Neoplasms
S Phase
PubMed
Stomach Neoplasms
Publications
Prostate
Urinary Bladder
Odds Ratio
Confidence Intervals
Control Groups
Neoplasms

Keywords

  • Breast cancer
  • Cyclin D1 (CCND1)
  • G870A polymorphism
  • Meta-analysis
  • Risk

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cyclin D1 G870A polymorphism and breast cancer risk : A meta-analysis involving 23,998 subjects. / Yang, June; Liu, Hong; Lu, Su; Gao, Maolong; Du, Qiuyue; Tang, Shou Ching.

In: Oncology Research, Vol. 19, No. 12, 07.06.2012, p. 519-525.

Research output: Contribution to journalArticle

Yang, June ; Liu, Hong ; Lu, Su ; Gao, Maolong ; Du, Qiuyue ; Tang, Shou Ching. / Cyclin D1 G870A polymorphism and breast cancer risk : A meta-analysis involving 23,998 subjects. In: Oncology Research. 2012 ; Vol. 19, No. 12. pp. 519-525.
@article{5328ffea8c0b4e5691fc47a26fcf834b,
title = "Cyclin D1 G870A polymorphism and breast cancer risk: A meta-analysis involving 23,998 subjects",
abstract = "Cyclin D1 (CCND1) plays an essential role in tumor development and progression through regulating the cell transition from G1 to the proliferative S phase. The CCND1 G870A polymorphism has been associated with an increased susceptibility to squamous cell carcinoma of the head and neck, bladder, prostate, and gastric cardiac cancers. There are a number of studies that explored the relationship between CCND1 G870A polymorphism and breast cancer risk, with inconsistent conclusions. In order to better define the predictive value of CCND1 G870A polymorphism in breast cancer, we searched PubMed and EBSCO for relevant publications. A total of 13 studies were indentified, which included 11,235 cases and 12,763 controls. We calculated the summary odds ratios and the corresponding 95{\%} confidence interval. Our meta-analysis showed that carriers of AA genotype have a significantly higher risk in developing breast cancer compared with that of GG genotype (OR = 1.08, 95{\%} CI = 1.01-1.17, p> = 0.03) in overall population. Furthermore, in subgroup analysis, CCND1 G870A polymorphism was associated with a marginally increased risk of breast cancer for Chinese compared to Caucasian populations with an OR = 1.14, 95{\%} CI = 1.00-1.20, ptrend = 0.06 for AA + GA versus GG, if the controls were hospital-based population with an OR = 1.21, 95{\%} CI = 0.99-1.47, p = 0.06 for AA versus GG and if the distributions of genotypes in control groups were consistent with the Hardy-Weinberg equilibrium (HWE) with an OR = 1.08, 95{\%} CI = 1.00-1.15, p = 0.04 for AA versus GA + GG. Our meta-analysis represents the largest study to date indicating that the G870A polymorphism in CCND1 confers an increased risk for breast cancer. Further studies are warranted to explore the preventive measures to detect and manage the breast cancers attributable to the G870A polymorphism.",
keywords = "Breast cancer, Cyclin D1 (CCND1), G870A polymorphism, Meta-analysis, Risk",
author = "June Yang and Hong Liu and Su Lu and Maolong Gao and Qiuyue Du and Tang, {Shou Ching}",
year = "2012",
month = "6",
day = "7",
doi = "10.3727/096504011X13148184434698",
language = "English (US)",
volume = "19",
pages = "519--525",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "12",

}

TY - JOUR

T1 - Cyclin D1 G870A polymorphism and breast cancer risk

T2 - A meta-analysis involving 23,998 subjects

AU - Yang, June

AU - Liu, Hong

AU - Lu, Su

AU - Gao, Maolong

AU - Du, Qiuyue

AU - Tang, Shou Ching

PY - 2012/6/7

Y1 - 2012/6/7

N2 - Cyclin D1 (CCND1) plays an essential role in tumor development and progression through regulating the cell transition from G1 to the proliferative S phase. The CCND1 G870A polymorphism has been associated with an increased susceptibility to squamous cell carcinoma of the head and neck, bladder, prostate, and gastric cardiac cancers. There are a number of studies that explored the relationship between CCND1 G870A polymorphism and breast cancer risk, with inconsistent conclusions. In order to better define the predictive value of CCND1 G870A polymorphism in breast cancer, we searched PubMed and EBSCO for relevant publications. A total of 13 studies were indentified, which included 11,235 cases and 12,763 controls. We calculated the summary odds ratios and the corresponding 95% confidence interval. Our meta-analysis showed that carriers of AA genotype have a significantly higher risk in developing breast cancer compared with that of GG genotype (OR = 1.08, 95% CI = 1.01-1.17, p> = 0.03) in overall population. Furthermore, in subgroup analysis, CCND1 G870A polymorphism was associated with a marginally increased risk of breast cancer for Chinese compared to Caucasian populations with an OR = 1.14, 95% CI = 1.00-1.20, ptrend = 0.06 for AA + GA versus GG, if the controls were hospital-based population with an OR = 1.21, 95% CI = 0.99-1.47, p = 0.06 for AA versus GG and if the distributions of genotypes in control groups were consistent with the Hardy-Weinberg equilibrium (HWE) with an OR = 1.08, 95% CI = 1.00-1.15, p = 0.04 for AA versus GA + GG. Our meta-analysis represents the largest study to date indicating that the G870A polymorphism in CCND1 confers an increased risk for breast cancer. Further studies are warranted to explore the preventive measures to detect and manage the breast cancers attributable to the G870A polymorphism.

AB - Cyclin D1 (CCND1) plays an essential role in tumor development and progression through regulating the cell transition from G1 to the proliferative S phase. The CCND1 G870A polymorphism has been associated with an increased susceptibility to squamous cell carcinoma of the head and neck, bladder, prostate, and gastric cardiac cancers. There are a number of studies that explored the relationship between CCND1 G870A polymorphism and breast cancer risk, with inconsistent conclusions. In order to better define the predictive value of CCND1 G870A polymorphism in breast cancer, we searched PubMed and EBSCO for relevant publications. A total of 13 studies were indentified, which included 11,235 cases and 12,763 controls. We calculated the summary odds ratios and the corresponding 95% confidence interval. Our meta-analysis showed that carriers of AA genotype have a significantly higher risk in developing breast cancer compared with that of GG genotype (OR = 1.08, 95% CI = 1.01-1.17, p> = 0.03) in overall population. Furthermore, in subgroup analysis, CCND1 G870A polymorphism was associated with a marginally increased risk of breast cancer for Chinese compared to Caucasian populations with an OR = 1.14, 95% CI = 1.00-1.20, ptrend = 0.06 for AA + GA versus GG, if the controls were hospital-based population with an OR = 1.21, 95% CI = 0.99-1.47, p = 0.06 for AA versus GG and if the distributions of genotypes in control groups were consistent with the Hardy-Weinberg equilibrium (HWE) with an OR = 1.08, 95% CI = 1.00-1.15, p = 0.04 for AA versus GA + GG. Our meta-analysis represents the largest study to date indicating that the G870A polymorphism in CCND1 confers an increased risk for breast cancer. Further studies are warranted to explore the preventive measures to detect and manage the breast cancers attributable to the G870A polymorphism.

KW - Breast cancer

KW - Cyclin D1 (CCND1)

KW - G870A polymorphism

KW - Meta-analysis

KW - Risk

UR - http://www.scopus.com/inward/record.url?scp=84861770761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861770761&partnerID=8YFLogxK

U2 - 10.3727/096504011X13148184434698

DO - 10.3727/096504011X13148184434698

M3 - Article

VL - 19

SP - 519

EP - 525

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 12

ER -